Bylvay denied as non-formulary by Blue Cross Blue Shield?
Non-formulary doesn't mean uncoverable. Most plans have a formulary-exception process: the appeal needs to show the formulary alternatives are inappropriate for your specific clinical situation.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Blue Cross Blue Shield typically requires
PFIC (Bylvay >=3 mo) or Alagille (Livmarli >=1 yr) genotype-confirmed. Pediatric hepatologist Rx.
What works in the appeal
Both FDA-approved for pediatric cholestatic pruritus (Bylvay Jul 2021 PFIC, Jun 2023 Alagille; Livmarli Sep 2021 Alagille, Mar 2024 PFIC). PEDFIC-1/2 + MARCH pivotal. Specialist letter from pediatric hepatologist. Orphan drug designation; no alternative IBAT inhibitor.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →